As the BAX/BCL-2 ratio seems to be the determinant for setting a threshold for cells undergoing apoptosis [36], we studied the effect of Lebein on BCL-2 and BAX protein expression to understand its therapeutic potential in melanoma. This evidence concerns the gene BCL2 and melanoma.